Thermo Fisher Scientific Inc (NYSE:TMO) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.

Other research analysts have also issued reports about the stock. Jefferies Group LLC raised their price target on shares of Thermo Fisher Scientific from $160.00 to $175.00 and gave the company a “hold” rating in a research report on Friday, April 28th. Deutsche Bank AG set a $200.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Saturday, June 10th. Bank of America Corporation raised their price target on shares of Thermo Fisher Scientific from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, May 9th. BTIG Research raised their price target on shares of Thermo Fisher Scientific from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Friday, April 28th. Finally, Leerink Swann set a $187.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, April 27th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $183.47.

Thermo Fisher Scientific (NYSE TMO) traded up 0.44% on Tuesday, hitting $173.99. 948,080 shares of the stock traded hands. The firm has a market capitalization of $68.07 billion, a PE ratio of 31.74 and a beta of 1.05. The stock has a 50 day moving average of $172.96 and a 200 day moving average of $157.13. Thermo Fisher Scientific has a 52 week low of $139.07 and a 52 week high of $176.92.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 26th. The medical research company reported $2.08 earnings per share for the quarter, beating analysts’ consensus estimates of $2.02 by $0.06. Thermo Fisher Scientific had a net margin of 11.58% and a return on equity of 15.73%. The company had revenue of $4.77 billion for the quarter, compared to analyst estimates of $4.68 billion. During the same period last year, the firm earned $1.80 earnings per share. The firm’s revenue was up 10.9% on a year-over-year basis. Equities research analysts anticipate that Thermo Fisher Scientific will post $9.22 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, July 17th. Shareholders of record on Thursday, June 15th will be given a dividend of $0.15 per share. The ex-dividend date is Tuesday, June 13th. This represents a $0.60 annualized dividend and a yield of 0.35%. Thermo Fisher Scientific’s payout ratio is presently 10.95%.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/06/27/thermo-fisher-scientific-inc-tmo-downgraded-to-buy-at-bidaskclub.html.

In other Thermo Fisher Scientific news, insider Thomas W. Loewald sold 1,532 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $168.76, for a total transaction of $258,540.32. Following the completion of the sale, the insider now directly owns 41,277 shares in the company, valued at $6,965,906.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Daniel P. Shine sold 4,688 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $171.88, for a total transaction of $805,773.44. Following the sale, the insider now owns 29,200 shares of the company’s stock, valued at $5,018,896. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,720 shares of company stock valued at $4,960,764. 0.49% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in the stock. Federated Investors Inc. PA raised its stake in shares of Thermo Fisher Scientific by 14.7% in the fourth quarter. Federated Investors Inc. PA now owns 9,431 shares of the medical research company’s stock worth $1,331,000 after buying an additional 1,210 shares during the last quarter. Fiera Capital Corp raised its stake in shares of Thermo Fisher Scientific by 32.9% in the fourth quarter. Fiera Capital Corp now owns 157,543 shares of the medical research company’s stock worth $22,230,000 after buying an additional 38,959 shares during the last quarter. Chevy Chase Trust Holdings Inc. raised its stake in shares of Thermo Fisher Scientific by 1.8% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 338,114 shares of the medical research company’s stock worth $51,935,000 after buying an additional 5,944 shares during the last quarter. Cigna Investments Inc. New acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $2,051,000. Finally, Whalerock Point Partners LLC raised its stake in shares of Thermo Fisher Scientific by 21.6% in the fourth quarter. Whalerock Point Partners LLC now owns 2,815 shares of the medical research company’s stock worth $398,000 after buying an additional 500 shares during the last quarter. Institutional investors and hedge funds own 86.94% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.